The Journal of Pathology Clinical Research · 2018 · 43 citations · 34 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyLymphoid NeoplasmsLymphoid TumorsTumor AntigensTumor ImmunopathologyTumor-associated AntigensImmunomodulatory AntibodiesImmunomodulatory BiologicsLymphoma Pathogenesis
CD74 is a type II transmembrane glycoprotein that functions as an MHC class II chaperone and displays diverse roles in immune responses. Recently, anti-CD74 immunotherapy has shown promise as an effective treatment strategy for lymphoid neoplasms in preclinical models. Using a human anti-CD74 antibody (SP7219), we defined the expression of CD74 protein in both normal and over 790 neoplastic hematolymphoid tissue samples. We found that CD74 is expressed broadly in normal B-cell compartments including primary and secondary lymphoid follicles and in the thymic medulla. The vast majority of lymphomas expressed CD74, including Hodgkin lymphomas (98%), B-cell lymphomas (96%), extranodal NK/T-cell lymphomas (88%), mature T-cell lymphomas (80%), and plasma cell myeloma (75%). Our findings confirm and expand previous observations regarding the expression of CD74 and suggest that CD74 expression on tumor cells may be directly targeted for immunomodulatory therapy for lymphoid and plasma cell malignancies.
34
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman, Michael S. Lawrence, Jonathan J. Keats et al. · Nature · 2011 · 1.4K citations · Full text
Life Sciences, Genetics, Oncology +15
Andreas Rosenwald, George W. Wright, Karen Leroy et al. · The Journal of Experimental Medicine · 2003 · 1.1K citations · Full text
Medicine, Hematology, Oncology +14
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Jonathan J. Keats, Rafaël Fonseca, Marta Chesi et al. · Cancer Cell · 2007 · 988 citations · Full text